Nonspecific binding of drugs to human liver microsomes.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2000-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1046/J.1365-2125.2000.00193.XPMID 10792203PMCID PMC2014956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man.

  2009cited by this paper
• Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

  1999cited by this paper
• Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.

  1998cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.

  1998cited by this paper
• Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4

  1998cited by this paper
• Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation.

  1998cited by this paper
• Autoactivation and activation of the cytochrome P450s.

  1998cited by this paper
• Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

  1997cited by this paper
• Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation.

  1997cited by this paper
• Examination of purported probes of human CYP2B6.

  1997cited by this paper
• Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.

  1997cited by this paper
• The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations.

  1996cited by this paper
• PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS

  1996cited by this paper
• Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.

  1996cited by this paper
• Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.

  1995cited by this paper
• Menadione-induced DNA fragmentation without 8-oxo-2'-deoxyguanosine formation in isolated rat hepatocytes.

  1995cited by this paper
• N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.

  1995cited by this paper
• Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

  1994cited by this paper
• Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.

  1994cited by this paper
• Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

  1994cited by this paper
• Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism

  1994cited by this paper
• Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions.

  1993cited by this paper
• In vitro approaches can predict human drug metabolism.

  1993cited by this paper
• Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques.

  1992cited by this paper
• The rational selection of drug interaction studies: implications of recent advances in drug metabolism.

  1992cited by this paper
• The rational selection of drug interaction studies: implications of recent advances in drug metabolism.

  1992cited by this paper
• Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

  1991cited by this paper
• Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats.

  1990cited by this paper
• Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone.

  1988cited by this paper
• Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.

  1988cited by this paper
• Characterisation of theophylline metabolism in human liver microsomes.

  1987cited by this paper
• E- and Z-10-hydroxylation of nortriptyline by human liver microsomes--methods and characterization.

  1983cited by this paper
• INVERTED RESPONSE OF ARGININE VASOPRESSIN TO POSTURAL CHANGE IN PATIENTS WITH ESSENTIAL HYPERTENSION

  1982cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Interaction of Cytochrome P450 3A4 with Fatty Acid Binding Protein 1 and Relevance to Drug Metabolism.

  2026cites this paper
• Arylacetamide deacetylase deficiency potentiates ketoconazole-induced inhibition of triazolam metabolism in mice

  2026cites this paper
• Human serum albumin immobilized on magnetizable beads: A rapid method for compound HSA binding study.

  2024cites this paper
• Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile

  2024influential citation
• In vitro screening of UGT2B10 in silico prioritized putative ligands from drugs used in the pediatric hematopoietic stem cell transplantation setting

  2024cites this paper
• Many human pharmaceuticals are weak inhibitors of the cytochrome P450 system in rainbow trout (Oncorhynchus mykiss) liver S9 fractions

  2024cites this paper
• HLM chip - A microfluidic approach to study the mechanistic basis of cytochrome P450 inhibition using immobilized human liver microsomes.

  2024cites this paper
• Comparison of commonly used and new methods to determine small molecule non-specific binding to human liver microsomes.

  2024cites this paper
• Inhibitory Effects of Tricyclic Antidepressants on Human Liver Microsomal Morphine Glucuronidation: Application of IVIVE to Predict Potential Drug-Drug Interactions in Humans.

  2023cites this paper
• Plasma protein-mediated uptake and contradictions to the free drug hypothesis: a critical review

  2023cites this paper
• Analyte recovery in LC-MS/MS bioanalysis: An old issue revisited.

  2022cites this paper
• Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism

  2022cites this paper
• Metabolism-Mediated Drug-Drug Interactions – Study Design, Data Analysis, and Implications for In Vitro Evaluations

  2022cites this paper
• HLM-beads: Rapid Assessment of Nonspecific Binding to Human Liver Microsomes Using Magnetizable Beads

  2021cites this paper
• High-throughput screening for identifying acetylcholinesterase inhibitors: Insights on novel inhibitors and the use of liver microsomes.

  2021cites this paper
• Investigation into MAO B–Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B

  2021influential citation
• How Science Is Driving Regulatory Guidances.

  2021cites this paper
• Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.

  2020cites this paper
• Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats

  2019cites this paper
• Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective

  2019cites this paper
• Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations

  2019cites this paper
• Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation

  2019cites this paper
• Mechanisms of metabolism interaction between p-cresol and mycophenolic acid.

  2019cites this paper
• Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

  2019cites this paper
• Physiologically Based Pharmacokinetic Modeling of Chemical Mixtures

  2018cites this paper
• Bioassay-guided isolation of triterpene from brown alga Padina boergesenii possess anti-inflammatory and anti-angiogenic potential with kinetic inhibition of β-carotene linoleate system

  2018cites this paper
• Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin

  2017cites this paper
• Effect of benzocaine and propranolol on phospholipid-based bilayers.

  2017cites this paper
• Advances in drug metabolism and pharmacogenetics research in Australia

  2017cites this paper
• Intracellular unbound drug concentrations : methodology and application for understanding cellular drug exposure

  2016cites this paper
• In Vitro Drug Metabolism Using Liver Microsomes

  2016cites this paper
• A Fragment-Based Approach for the Computational Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes

  2016cites this paper
• Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.

  2016influential citation
• Methodology and application for understanding cellular drug exposure

  2016cites this paper
• Ste24p Mediates Proteolysis of Both Isoprenylated and Non-prenylated Oligopeptides*

  2016cites this paper
• Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme ‘active site’ pocket plays a relatively ‘passive role’ in some enzyme-substrate interactions

  2016influential citation
• SYSTEM-DEPENDENT METABOLISM OF DRUGS BY CYTOCHROME P450: THE MECHANISTIC BASIS FOR WHY HUMAN LIVER MICROSOMES ARE SUPERIOR TO HUMAN HEPATOCYTES AT METABOLIZING MIDAZOLAM BUT INFERIOR AT METABOLIZING DESLORATADINE

  2015cites this paper
• A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data

  2015cites this paper
• DMD066597 1744..1750

  2015cites this paper
• The non-specific binding of tyrosine kinase inhibitors to human liver microsomes

  2015cites this paper
• Plasma Protein Binding of Challenging Compounds.

  2015cites this paper
• Membrane–drug interactions studied using model membrane systems

  2015cites this paper
• The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments

  2015cites this paper
• DMD065870 1468..1476

  2015cites this paper
• The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes

  2015cites this paper
• In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism

  2015influential citation
• Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists

  2015cites this paper
• Transporter-Mediated Uptake of UDP–Glucuronic Acid by Human Liver Microsomes: Assay Conditions, Kinetics, and Inhibition

  2015cites this paper
• Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions

  2015cites this paper
• Microsoft Word-35726944-file00.docx

  2015cites this paper
• The Effects of Bovine Serum Albumin on Kinetic Characterization of Human Liver Microsomal CYP2C19 and CYP2E1 Activities

  2015cites this paper
• Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins

  2014cites this paper
• Development of a Physiologically-Based Pharmacokinetic Model of the Rat Central Nervous System

  2014cites this paper
• Untersuchung zur Gewebsaufnahme und Gewebsbindung ausgewählter Anthrachinone

  2014cites this paper
• Morphine Glucuronidation and Glucosidation Represent Complementary Metabolic Pathways That Are Both Catalyzed by UDP-Glucuronosyltransferase 2B7: Kinetic, Inhibition, and Molecular Modeling Studies

  2014cites this paper
• Pharmacometric analyses of drug exposure and response data

  2013cites this paper
• Activity and Enzyme Kinetics of Human UDP-Glucuronosyltransferases : Studies of Psilocin Glucuronidation and the Effects of Albumin on the Enzyme Kinetic Mechanism

  2013cites this paper
• DMD051656 1273..1284

  2013cites this paper
• Integration of In Vitro Binding Mechanism Into the Semiphysiologically Based Pharmacokinetic Interaction Model Between Ketoconazole and Midazolam

  2013cites this paper
• When is protein binding important?

  2013cites this paper
• The Glucuronidation of R- and S-Lorazepam: Human Liver Microsomal Kinetics, UDP-Glucuronosyltransferase Enzyme Selectivity, and Inhibition by Drugs

  2013cites this paper
• Characterisation of the unique Campylobacter jejuni cytochrome P450, CYP172A1

  2013cites this paper
• Effect of Albumin on Human Liver Microsomal and Recombinant CYP1A2 Activities: Impact on In Vitro-In Vivo Extrapolation of Drug Clearance

  2012cites this paper
• Role and Clinical Consequences of Human UDP-Glucuronosyltransferases

  2012cites this paper
• In Vitro–In Vivo Correlations of Hepatic Drug Clearance

  2012cites this paper
• Enzyme Kinetics of Drug‐Metabolizing Reactions and Drug–Drug Interactions

  2012cites this paper
• Measuring in vitro biotransformation rates of super hydrophobic chemicals in rat liver s9 fractions using thin-film sorbent-phase dosing.

  2012cites this paper
• Correction for Nonspecific Binding to Various Components of Ultrafiltration Apparatus and Impact on Estimating In Vivo Rat Clearance for a Congeneric Series of 5-Ethyl, 5-n-Alkyl Barbituric Acids

  2011cites this paper
• Effects of Ketamine on Human UDP-Glucuronosyltransferases In Vitro Predict Potential Drug-Drug Interactions Arising from Ketamine Inhibition of Codeine and Morphine Glucuronidation

  2011cites this paper
• In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance

  2011cites this paper
• Application of the Fluorescent Probe 1-Anilinonaphthalene-8-Sulfonate to the Measurement of the Nonspecific Binding of Drugs to Human Liver Microsomes

  2011cites this paper
• Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes.

  2011cites this paper
• Characterizing low affinity epibatidine binding to α4β2 nicotinic acetylcholine receptors with ligand depletion and nonspecific binding

  2011cites this paper
• Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.

  2011cites this paper
• Scaling in vivo pharmacokinetics from in vitro metabolic stability data in drug discovery.

  2010cites this paper
• In Vitro–In Vivo Extrapolation Predicts Drug–Drug Interactions Arising from Inhibition of Codeine Glucuronidation by Dextropropoxyphene, Fluconazole, Ketoconazole, and Methadone in Humans

  2010cites this paper
• Lack of appreciable species differences in nonspecific microsomal binding.

  2010cites this paper
• Assessment of in silico models for fraction of unbound drug in human liver microsomes

  2010cites this paper
• Role of Human UGT2B10 in N-Glucuronidation of Tricyclic Antidepressants, Amitriptyline, Imipramine, Clomipramine, and Trimipramine

  2010cites this paper
• Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine.

  2010cites this paper
• The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential

  2010cites this paper
• The In Vitro Characterization of Inhibitory Drug–Drug Interactions Involving UDP-Glucuronosyltransferase

  2010cites this paper
• Microsoft Word-47780631-file00

  2010cites this paper
• Microsoft Word-41588726-file00.docx

  2010cites this paper
• Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants

  2009influential citation
• Kinetics membrane disruption due to drug interactions of chlorpromazine hydrochloride.

  2009cites this paper
• Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.

  2009cites this paper
• The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities

  2008cites this paper
• Local Kinetics and Dynamics of Xenobiotics

  2008cites this paper
• Tolerability and efficacy of oral loading of levetiracetam

  2008cites this paper
• Studying cytochrome P450 kinetics in drug metabolism.

  2008cites this paper
• Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance.

  2008cites this paper
• Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase

  2008cites this paper
• The “Albumin Effect” and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9

  2008cites this paper
• Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations

  2008cites this paper
• PHYSICOCHEMICAL DETERMINANTS OF THE NON-SPECIFIC BINDING OF DRUGS TO HUMAN LIVER MICROSOMES

  2008cites this paper
• Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance

  2008cites this paper
• Studying cytochrome P450 kinetics in drug metabolism

  2008cites this paper
• Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation.

  2007cites this paper
• Development of Three Parallel Cytochrome P450 Enzyme Affinity Detection Systems Coupled On-line to Gradient High-Performance Liquid Chromatography

  2007cites this paper